ASTRO Release: Stereotactic Body Radiation Therapy Shows Advances for Inoperable, Non-Small Cell Lung Cancer Patients

BOSTON, Oct. 29, 2012 (GLOBE NEWSWIRE) -- Stereotactic body radiation therapy (SBRT) yielded higher overall survival rates and low toxicity for patients with inoperable, non-small cell lung cancer (NSCLC) in comparison to conventional radiation therapy, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 54th Annual Meeting. The study follows a 2010 report1 on operable patients with NSCLC.